Safety of risdiplam in spinal muscular atrophy patients after short‐term treatment with nusinersen

Documents similaires

• Transverse interlaminar ultrasound‐guided C1‐C2 puncture for the intrathecal administration of nusinersen in patients with spinal muscular atrophy
  par: Qing Yuan, et autres
  Publié: (2024)
• Six‐minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen
  par: Alessandra Govoni, et autres
  Publié: (2024)
• Ultrasound assisted versus landmark based intrathecal administration of nusinersen in adults with spinal muscular atrophy disease: A randomized trial
  par: Bruno Antonio Zanfini, et autres
  Publié: (2024)
• Secondary outcomes of scoliosis surgery in disease‐modifying treatment‐naïve patients with spinal muscular atrophy type 2 and nonambulant type 3
  par: Chiara Brusa, et autres
  Publié: (2024)
• Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates
  par: Vivek Mundada, et autres
  Publié: (2024)